[Table_Page] 跟踪分析|银行 证券研究报告 [Table_Title] 银行投资观察 20250316 兵马已动，粮草先行 ——坚定看好顺周期复苏 [Table_Summary] 核心观点： | [Table_Gr ade] 行业评级 | 买入 | | --- | --- | | 前次评级 | 买入 | | 报告日期 | 2025-03-16 | [Table_PicQuote] 相对市场表现 [分析师： Table_Author]倪军 SAC 执证号：S0260518020004 021-38003646 nijun@gf.com.cn 分析师： 许洁 SAC 执证号：S0260518080004 SFC CE No. BNU965 021-38003625 xujie@gf.com.cn -14% -5% 4% 12% 21% 30% 03/24 05/24 08/24 10/24 12/24 03/25 银行 沪深300 请注意，倪军并非香港证券及期货事务监察委员会的注册 持牌人，不可在香港从事受监管活动。 [Table_ 相关研究： DocReport] 识别风险，发现价值 请务必阅读末页 ...

[Table_Page] 年报点评|银行 证券研究报告 展望 2025 年，预计随着资产端结构调整到位和负债成本管控持续，净 息差下行幅度有望收窄。（2）零售不良率环比下行，对公不良率环比上 行。24 年末不良贷款率 1.06%，同比环比均持平。零售不良率 1.39%， 较 24Q3 末/23 年末分别变动-4bp、+2bp，按揭、经营贷不良率环比上 升 3bp、19bp，消费贷、信用卡不良率环比下降 11bp、14bp。对公不 良率 0.70%，较 24Q3 末/23 年末分别变动+4bp、+7bp，预计主要是 制造业和房地产业风险暴露，不良率分别较年初上行 47bp、36bp。24 年末关注贷款率 1.93%，较 24Q3 末/23 年末分别变动-4bp、+18bp； 逾期率 1.52%，较 24Q3 末/23 年末分别变动-3bp、+9bp；测算 24A 不 良净生成率 2.37%，同比上升 10bp。24 年末拨备覆盖率 250.71%。 [Table_PicQuote] 相对市场表现 -12% -3% 6% 14% 23% 32% 03/24 05/24 07/24 09/24 11/24 01/2 ...

Investment Rating - The report assigns a "Buy" rating to the company [3]. Core Views - The company is positioned as a leader in the field of regenerative medicine, particularly in neurosurgery, with a diverse range of products driving significant revenue growth [19][25]. - The implementation of centralized procurement across multiple regions is expected to be a key factor in the company's performance release [19]. - The company has a stable management and ownership structure, with a stock incentive plan reflecting confidence in future business development [39][46]. Financial Forecast - The company is projected to achieve revenues of 286 million yuan in 2024, 367 million yuan in 2025, and 482 million yuan in 2026, with corresponding EPS of 1.09 yuan, 1.45 yuan, and 1.94 yuan respectively [2][9]. - The expected growth rates for revenue are 23.7% in 2024, 28.6% in 2025, and 31.3% in 2026 [2]. Business Overview - The company has a rich portfolio of neurosurgical products that meet various clinical needs, including artificial dura mater patches and hemostatic products [19][21]. - The company has successfully entered centralized procurement in several provinces, enhancing market penetration and sales volume [24][25]. - The company has established a strong international presence, with sales networks covering nearly 90 countries and regions, contributing to a 25.71% increase in overseas sales [25][26]. Product Development - The company has developed a comprehensive product matrix in neurosurgery, including artificial dura mater patches, craniofacial repair systems, and absorbable hemostatic products [19][21]. - The absorbable regenerated cellulose product is expected to break the long-standing import monopoly in the domestic market [24][25]. - The company has received multiple medical device registrations, enhancing its competitive edge in the market [19][20]. Management and Incentives - The management team possesses extensive experience in the medical device industry, contributing to the company's strategic direction and operational efficiency [39][43]. - The stock incentive plan aims to align employee interests with the company's long-term growth objectives, fostering motivation among key personnel [46][47].

Investment Rating - The investment rating for the company is "Buy" with a current price of 11.97 CNY and a reasonable value of 17.91 CNY [2]. Core Views - The company is undergoing a transformation period, with retail growth slowing and declining yields. However, long-term risk preference adjustments are favorable for sustainable operations. The expected growth rates for the company's net profit attributable to shareholders are 0.67% and 3.00% for 2025 and 2026, respectively, with corresponding EPS of 2.16 CNY and 2.23 CNY per share [9]. Financial Performance Summary - In 2024, the company's revenue, PPOP, and net profit attributable to shareholders decreased by 10.9%, 10.8%, and 4.2% year-on-year, respectively. The growth rates for these metrics improved compared to the first three quarters of 2024 [8][11]. - The loan scale decreased by 1.0% year-on-year by the end of 2024, with retail high-risk loans being reduced significantly. Retail loans fell by 10.6%, primarily due to reductions in consumer loans (70.6 billion CNY), credit cards (83.4 billion CNY), and operational loans (79.1 billion CNY). Conversely, corporate loans increased by 17.0% year-on-year [8][9]. - The net interest margin for 2024 was 1.87%, a decrease of 51 basis points year-on-year, influenced by market changes and proactive asset structure adjustments [8][11]. Asset Quality and Risk Indicators - By the end of 2024, the non-performing loan ratio was 1.06%, remaining stable year-on-year and quarter-on-quarter. The retail non-performing loan ratio was 1.39%, showing slight fluctuations, while the corporate non-performing loan ratio was 0.70%, reflecting increased risk exposure in manufacturing and real estate sectors [4][11]. - The provision coverage ratio at the end of 2024 was 250.71%, indicating a strong buffer against potential loan losses [4][11]. Market Performance - The company's stock performance relative to the market showed a decline of 12% from March 2024 to March 2025, compared to the CSI 300 index [6].

[Table_Page] 公司深度研究|工程咨询服务Ⅱ 证券研究报告 | [Table_Title] 太极实业（600667.SH） | | --- | | 半导体制造及工程服务商，有望受益区位优 | 势加持、集团资源倾斜 [Table_Summary] 核心观点： | 盈利预测： | | | | | | | --- | --- | --- | --- | --- | --- | | [Table_Finance] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业收入（百万元） | 35195 | 39377 | 39612 | 41303 | 41600 | | 增长率（ % ） | 44.9% | 11.9% | 0.6% | 4.3% | 0.7% | | EBITDA（百万元） | 565 | 1785 | 1689 | 1778 | 1900 | | 归母净利润（百万元） | -743 | 730 | 733 | 757 | 792 | | 增长率（ % ） | -181.7% | 198.4% | 0.3% | 3.3% | 4.6% | | EPS（元 ...

| [Table_Title] 太极实业（600667.SH） | | --- | | 半导体制造及工程服务商，有望受益区位优 | 势加持、集团资源倾斜 [Table_Summary] 核心观点： | 盈利预测： | | | | | | | --- | --- | --- | --- | --- | --- | | [Table_Finance] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业收入（百万元） | 35195 | 39377 | 39612 | 41303 | 41600 | | 增长率（ % ） | 44.9% | 11.9% | 0.6% | 4.3% | 0.7% | | EBITDA（百万元） | 565 | 1785 | 1689 | 1778 | 1900 | | 归母净利润（百万元） | -743 | 730 | 733 | 757 | 792 | | 增长率（ % ） | -181.7% | 198.4% | 0.3% | 3.3% | 4.6% | | EPS（元/股） | -0.35 | 0.35 | 0.35 | 0.36 | ...

[Table_Page] 公司深度研究|计算机设备 证券研究报告 | Table_Invest] [公司评级 | 买入 | | --- | --- | | 当前价格 | 54.94 元 | | 合理价值 | 78.77 元 | | 报告日期 | 2025-03-13 | 基本数据 [Table_BaseInfo] | 总股本/流通股本（百万股） | 177.28/116.14 | | --- | --- | | 总市值/流通市值（百万元） | 9739.8/6380.7 | | 一年内最高/最低（元） | 58.70/25.46 | | 30 日日均成交量/成交额（百万） | 7.95/416.89 | | 近 3 个月/6 个月涨跌幅（%） | 18.87/69.16 | [Table_PicQuote] 相对市场表现 [分析师： Table_Author]刘雪峰 SAC 执证号：S0260514030002 SFC CE No. BNX004 021-38003675 -12% 15% 42% 68% 95% 122% 03-24 05-24 07-24 09-24 11-24 01-25 03-25 锐 ...

Investment Rating - The report assigns an "Accumulate-A/Accumulate-H" rating to the company [4]. Core Views - The company benefits from its unique position as the only publicly listed highway operator in Anhui Province, leveraging local resources and cost advantages to maintain industry-leading profit margins and returns [10][18]. - The provincial road network expansion and inter-provincial connectivity are key growth drivers, with a projected CAGR of around 5% from 2023 to 2035 [10]. - The company is expected to see improved fundamentals in the short to medium term due to macroeconomic support and the ramp-up of new highway capacities [10]. - Long-term prospects are bolstered by the ongoing development of the provincial transportation network, which is anticipated to enhance traffic flow and revenue generation [10]. Financial Forecast - Revenue is projected to grow from 5,206 million RMB in 2022 to 6,631 million RMB in 2023, before declining to 4,208 million RMB in 2025 [2]. - Net profit is expected to fluctuate, with estimates of 1,445 million RMB in 2022, increasing to 1,660 million RMB in 2023, and then decreasing to 1,519 million RMB in 2024 [2]. - The company's EPS is forecasted to be 0.87 RMB in 2022, rising to 1.00 RMB in 2023, and then slightly declining to 0.92 RMB in 2024 [2]. Company Overview - The company was established in 1996 and is the first highway company listed in Hong Kong, focusing on the operation of toll roads in Anhui Province [18]. - It operates 10 toll roads, with a total operational mileage of 609 kilometers, primarily located in key traffic areas of Anhui [23]. - The average remaining toll collection period for its projects is approximately 10.8 years, which is in line with industry standards [29]. Cost and Profitability - The company enjoys a cost advantage due to lower construction costs in Anhui, attributed to favorable terrain and lower land acquisition costs [51]. - The average operating cost per kilometer is significantly lower than industry peers, contributing to its strong profitability metrics [52]. - The company has maintained a high gross margin, with a reported gross margin of 63% in 2023, and a net profit margin of 41% [33]. Dividend Policy - The company has increased its dividend payout ratio to 60% since 2021, reflecting its commitment to shareholder returns [52]. - This high dividend yield, combined with robust profit recovery, has led to a significant increase in the company's stock price, outperforming peers since 2020 [52].

ia[Table_Title] 皖通高速(600012.SH)/安徽皖通高 速公路(00995.HK) 核心红利深植皖地，引流拓流并举发力 [Table_Summary] 核心观点： 盈利预测： | [Table_Finance] | 2022A | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 5206 | 6631 | 6181 | 4208 | 4332 | | 增长率（ % ） | 32.8% | 27.4% | -6.8% | -31.9% | 3.0% | | EBITDA（百万元） | 3015 | 3349 | 3369 | 3742 | 3907 | | 归母净利润（百万元） | 1445 | 1660 | 1519 | 1747 | 1828 | | 增长率（ % ） | -4.6% | 14.9% | -8.5% | 15.0% | 4.6% | | EPS（元/股） | 0.87 | 1.00 | 0.92 | 1.05 | 1.10 | | 市盈率（P/E） | ...

[Table_Page] 公司深度研究|计算机设备 证券研究报告 | Table_Invest] [公司评级 | 买入 | | --- | --- | | 当前价格 | 54.94 元 | | 合理价值 | 78.77 元 | | 报告日期 | 2025-03-13 | 基本数据 [Table_BaseInfo] | 总股本/流通股本（百万股） | 177.28/116.14 | | --- | --- | | 总市值/流通市值（百万元） | 9739.8/6380.7 | | 一年内最高/最低（元） | 58.70/25.46 | | 30 日日均成交量/成交额（百万） | 7.95/416.89 | | 近 3 个月/6 个月涨跌幅（%） | 18.87/69.16 | [Table_PicQuote] 相对市场表现 [分析师： Table_Author]刘雪峰 SAC 执证号：S0260514030002 SFC CE No. BNX004 021-38003675 -12% 15% 42% 68% 95% 122% 03-24 05-24 07-24 09-24 11-24 01-25 03-25 锐 ...